US demand for vaccines will advance 5.6 percent annually through 2014, driven by the development of new vaccines to treat complex human diseases, such as cancer. Public health recommendations for adult and adolescent immunization will produce continued strong sales in this segment, which has reached the level of pediatric vaccines sales.
This study analyzes the $10.8 billion US vaccines industry. It presents historical demand data for the years 1999, 2004 and 2009, and forecasts for 2014 and 2019 by vaccine type (e.g., pediatric, adult and adolescent, pandemic influenza, biodefense, developmental, travel, livestock, companion animal, poultry).
The study also considers market environment factors, details industry structure, evaluates company market share and profiles 18 industry competitors, including Sanofi-Aventis, Merck and GlaxoSmithKline.